JP2022542431A5 - - Google Patents
Info
- Publication number
- JP2022542431A5 JP2022542431A5 JP2022506359A JP2022506359A JP2022542431A5 JP 2022542431 A5 JP2022542431 A5 JP 2022542431A5 JP 2022506359 A JP2022506359 A JP 2022506359A JP 2022506359 A JP2022506359 A JP 2022506359A JP 2022542431 A5 JP2022542431 A5 JP 2022542431A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- variable region
- chain variable
- multispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962880347P | 2019-07-30 | 2019-07-30 | |
| US62/880,347 | 2019-07-30 | ||
| PCT/US2020/070334 WO2021022304A2 (en) | 2019-07-30 | 2020-07-30 | MULTISPECIFIC BINDING COMPOUNDS THAT BIND TO LRRC15 AND CD3ε |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022542431A JP2022542431A (ja) | 2022-10-03 |
| JP2022542431A5 true JP2022542431A5 (enExample) | 2023-08-08 |
Family
ID=72145539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506359A Pending JP2022542431A (ja) | 2019-07-30 | 2020-07-30 | 二重特異性抗ｌｒｒｃ１５及びｃｄ３イプシロン抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230374130A1 (enExample) |
| EP (1) | EP4004050A2 (enExample) |
| JP (1) | JP2022542431A (enExample) |
| CN (2) | CN114341186B (enExample) |
| CA (1) | CA3146341A1 (enExample) |
| WO (1) | WO2021022304A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240294640A1 (en) * | 2021-06-02 | 2024-09-05 | Qure Biotechnology (Shanghai) Co., Ltd. | Anti-cd3 antibody variant, fusion protein, and application |
| JP2024530166A (ja) * | 2021-08-04 | 2024-08-16 | アブプロ コーポレーション | Ｃｄ３標的化抗体及びそれらの使用 |
| WO2023036215A1 (zh) * | 2021-09-08 | 2023-03-16 | 上海齐鲁制药研究中心有限公司 | 双特异性抗原结合分子及其应用 |
| CN116253802A (zh) * | 2021-12-10 | 2023-06-13 | 苏州泽璟生物制药股份有限公司 | 包含lrrc15抗原结合结构域的多特异性t细胞接合剂 |
| CA3260738A1 (en) * | 2022-06-27 | 2024-01-04 | Scg Cell Therapy Pte. Ltd. | Bispecific antibodies for HBV surface antigen (AGHBS) and CD3 and their uses |
| CN119654163A (zh) * | 2022-08-09 | 2025-03-18 | 魁尔斯弗生物治疗股份有限公司 | 与clec12a结合的抗体 |
| JP2025534696A (ja) * | 2022-10-12 | 2025-10-17 | ミシク セラピューティクス， インコーポレイテッド | Ｌｒｒｃ１５結合タンパク質構築物及びそれらの使用 |
| WO2024094017A1 (zh) | 2022-11-01 | 2024-05-10 | 上海齐鲁制药研究中心有限公司 | 一种针对磷脂酰肌醇蛋白聚糖3的双特异性抗体及其应用 |
| WO2025064369A1 (en) * | 2023-09-18 | 2025-03-27 | Modernatx, Inc. | Humanized anti-cd3 binding molecules and uses thereof |
| IL327045A (en) | 2023-10-05 | 2026-05-01 | Capstan Therapeutics Inc | Structure-restricted ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025201242A1 (en) * | 2024-03-25 | 2025-10-02 | Tavotek Biotherapeutics (Hong Kong) Limited | Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| EP1578447A4 (en) | 2002-10-31 | 2009-06-03 | Genentech Inc | METHOD AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| US20050239700A1 (en) * | 2003-10-14 | 2005-10-27 | Biogen Idec Inc. | Treatment of cancer using antibodies to LRRC15 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US20090155275A1 (en) | 2007-07-31 | 2009-06-18 | Medimmune, Llc | Multispecific epitope binding proteins and uses thereof |
| KR101589785B1 (ko) | 2009-03-10 | 2016-01-28 | 바이오젠 엠에이 인코포레이티드 | 항-ｂｃｍａ 항체 |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2011110642A2 (en) | 2010-03-10 | 2011-09-15 | Genmab A/S | Monoclonal antibodies against c-met |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| CA2898100C (en) * | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| WO2014144357A1 (en) | 2013-03-15 | 2014-09-18 | Merck Patent Gmbh | Tetravalent bispecific antibodies |
| US10259887B2 (en) * | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| HRP20231134T1 (hr) * | 2015-06-16 | 2024-01-05 | F. Hoffmann - La Roche Ag | Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu |
| AU2016302881B2 (en) * | 2015-08-03 | 2022-09-15 | Bristol-Myers Squibb Company | Monoclonal antibodies against BCMA |
| EP3383910A1 (en) * | 2015-11-30 | 2018-10-10 | AbbVie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
| ES2810755T3 (es) | 2015-11-30 | 2021-03-09 | Abbvie Inc | Conjugados fármaco-anticuerpo anti-lrrc15 humano y métodos para su uso |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| MY200988A (en) * | 2016-09-14 | 2024-01-27 | Teneobio Inc | CD3 Binding Antibodies |
| BR112019007281A2 (pt) | 2016-10-14 | 2019-07-09 | Xencor Inc | proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente |
-
2020
- 2020-07-30 EP EP20758074.7A patent/EP4004050A2/en not_active Withdrawn
- 2020-07-30 JP JP2022506359A patent/JP2022542431A/ja active Pending
- 2020-07-30 CN CN202080061357.4A patent/CN114341186B/zh active Active
- 2020-07-30 CA CA3146341A patent/CA3146341A1/en active Pending
- 2020-07-30 US US17/588,086 patent/US20230374130A1/en active Pending
- 2020-07-30 WO PCT/US2020/070334 patent/WO2021022304A2/en not_active Ceased
- 2020-07-30 CN CN202510512319.0A patent/CN120842421A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7853992B2 (ja) | クローディン１８ａ２及びｃｄ３に対する二重特異性抗体及びその使用 | |
| JP7549961B2 (ja) | 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット | |
| JP6721590B2 (ja) | 多重特異性抗体 | |
| JP2024532485A5 (enExample) | ||
| JP5938473B2 (ja) | 多価抗原結合Ｆｖ分子 | |
| JP2023538945A5 (enExample) | ||
| JP2021508458A (ja) | Ｒｏｒ１特異性抗原結合分子 | |
| JP2021534096A5 (enExample) | ||
| JP2021512630A5 (enExample) | ||
| JP2023518134A5 (enExample) | ||
| CN106456760B (zh) | 人源化的抗-Tau(pS422)抗体脑穿梭物及其应用 | |
| JP2010500876A5 (enExample) | ||
| FI3582806T3 (fi) | Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja | |
| JP2018503380A5 (enExample) | ||
| JP2024541048A5 (enExample) | ||
| RS58352B1 (sr) | Multivalentni antigen-vezujući fv molekul | |
| JP2021533159A5 (enExample) | ||
| JP2017506234A5 (enExample) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JP2021522347A5 (enExample) | ||
| JP2021511782A (ja) | 安定化された免疫グロブリンドメイン | |
| JP2020502233A5 (enExample) | ||
| JP2021500873A (ja) | システイン操作された抗原結合分子 | |
| JP2023548529A5 (enExample) | ||
| JP2024001073A5 (enExample) |